How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
46
MIST Quote, Financials, Valuation and Earnings
Last price:
$1.97
Seasonality move
:
-17.08%
Day range:
$1.81 - $1.86
52-week range:
$1.12 - $2.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.11x
Volume:
129.5K
Avg. volume:
367.4K
1-year change:
-35.76%
Market cap:
$98.7M
Revenue:
$1M
EPS (TTM):
-$0.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MIST
Milestone Pharmaceuticals
|
-- | -$0.18 | -100% | -53.13% | -- |
|
AUPH
Aurinia Pharmaceuticals
|
$57.7M | $0.02 | 32.93% | -24.07% | -- |
|
EDSA
Edesa Biotech
|
-- | -- | -- | -- | $20.50 |
|
EPIX
ESSA Pharma
|
-- | -$0.20 | -- | -26.82% | -- |
|
LEXX
Lexaria Bioscience
|
$100K | -- | -31.04% | -- | -- |
|
XENE
Xenon Pharmaceuticals
|
-- | -$0.79 | -- | -28.14% | $57.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MIST
Milestone Pharmaceuticals
|
$1.85 | -- | $98.7M | -- | $0.00 | 0% | -- |
|
AUPH
Aurinia Pharmaceuticals
|
$8.98 | -- | $1.3B | -- | $0.00 | 0% | 5.88x |
|
EDSA
Edesa Biotech
|
$1.75 | $20.50 | $6.1M | -- | $0.00 | 0% | 17.02x |
|
EPIX
ESSA Pharma
|
$1.61 | -- | $71.5M | -- | $0.00 | 0% | -- |
|
LEXX
Lexaria Bioscience
|
$2.21 | -- | $38.6M | -- | $0.00 | 0% | 58.77x |
|
XENE
Xenon Pharmaceuticals
|
$38.42 | $57.67 | $2.9B | -- | $0.00 | 0% | 221.08x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MIST
Milestone Pharmaceuticals
|
-- | 0.713 | -- | -- |
|
AUPH
Aurinia Pharmaceuticals
|
-- | 0.341 | -- | 4.90x |
|
EDSA
Edesa Biotech
|
-- | 0.099 | -- | -- |
|
EPIX
ESSA Pharma
|
-- | 0.357 | -- | -- |
|
LEXX
Lexaria Bioscience
|
-- | 5.584 | -- | 55.84x |
|
XENE
Xenon Pharmaceuticals
|
-- | 0.783 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MIST
Milestone Pharmaceuticals
|
-- | -$9.6M | -- | -- | -- | -$7M |
|
AUPH
Aurinia Pharmaceuticals
|
$61.7M | $11.7M | -5.99% | -5.99% | 23.63% | $16.9M |
|
EDSA
Edesa Biotech
|
-- | -$967.2K | -- | -- | -- | -$967K |
|
EPIX
ESSA Pharma
|
-- | -$7M | -- | -- | -- | -$3.4M |
|
LEXX
Lexaria Bioscience
|
$84K | -$1.7M | -93.31% | -93.31% | -2074.9% | -$1.3M |
|
XENE
Xenon Pharmaceuticals
|
-- | -$73.7M | -- | -- | -- | -$51.7M |
Milestone Pharmaceuticals vs. Competitors
-
Which has Higher Returns MIST or AUPH?
Aurinia Pharmaceuticals has a net margin of -- compared to Milestone Pharmaceuticals's net margin of 21.17%. Milestone Pharmaceuticals's return on equity of -- beat Aurinia Pharmaceuticals's return on equity of -5.99%.
Company Gross Margin Earnings Per Share Invested Capital MISTMilestone Pharmaceuticals-- -$0.14 -- AUPHAurinia Pharmaceuticals91.1% $0.10 $388M -
What do Analysts Say About MIST or AUPH?
Milestone Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 454.05%. On the other hand Aurinia Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 20.67%. Given that Milestone Pharmaceuticals has higher upside potential than Aurinia Pharmaceuticals, analysts believe Milestone Pharmaceuticals is more attractive than Aurinia Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings MISTMilestone Pharmaceuticals0 0 0 AUPHAurinia Pharmaceuticals0 0 0 -
Is MIST or AUPH More Risky?
Milestone Pharmaceuticals has a beta of 1.826, which suggesting that the stock is 82.646% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.752%.
-
Which is a Better Dividend Stock MIST or AUPH?
Milestone Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Pharmaceuticals pays -- of its earnings as a dividend. Aurinia Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIST or AUPH?
Milestone Pharmaceuticals quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals quarterly revenues of $67.8M. Milestone Pharmaceuticals's net income of -$9.4M is lower than Aurinia Pharmaceuticals's net income of $14.4M. Notably, Milestone Pharmaceuticals's price-to-earnings ratio is -- while Aurinia Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Pharmaceuticals is -- versus 5.88x for Aurinia Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MISTMilestone Pharmaceuticals-- -- -- -$9.4M AUPHAurinia Pharmaceuticals5.88x -- $67.8M $14.4M
-
Which has Higher Returns MIST or EDSA?
Edesa Biotech has a net margin of -- compared to Milestone Pharmaceuticals's net margin of --. Milestone Pharmaceuticals's return on equity of -- beat Edesa Biotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MISTMilestone Pharmaceuticals-- -$0.14 -- EDSAEdesa Biotech-- -$0.29 -- -
What do Analysts Say About MIST or EDSA?
Milestone Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 454.05%. On the other hand Edesa Biotech has an analysts' consensus of $20.50 which suggests that it could grow by 1071.43%. Given that Edesa Biotech has higher upside potential than Milestone Pharmaceuticals, analysts believe Edesa Biotech is more attractive than Milestone Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings MISTMilestone Pharmaceuticals0 0 0 EDSAEdesa Biotech0 0 0 -
Is MIST or EDSA More Risky?
Milestone Pharmaceuticals has a beta of 1.826, which suggesting that the stock is 82.646% more volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.837%.
-
Which is a Better Dividend Stock MIST or EDSA?
Milestone Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Pharmaceuticals pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIST or EDSA?
Milestone Pharmaceuticals quarterly revenues are --, which are smaller than Edesa Biotech quarterly revenues of --. Milestone Pharmaceuticals's net income of -$9.4M is lower than Edesa Biotech's net income of -$962.1K. Notably, Milestone Pharmaceuticals's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Pharmaceuticals is -- versus 17.02x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MISTMilestone Pharmaceuticals-- -- -- -$9.4M EDSAEdesa Biotech17.02x -- -- -$962.1K
-
Which has Higher Returns MIST or EPIX?
ESSA Pharma has a net margin of -- compared to Milestone Pharmaceuticals's net margin of --. Milestone Pharmaceuticals's return on equity of -- beat ESSA Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MISTMilestone Pharmaceuticals-- -$0.14 -- EPIXESSA Pharma-- -$0.14 -- -
What do Analysts Say About MIST or EPIX?
Milestone Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 454.05%. On the other hand ESSA Pharma has an analysts' consensus of -- which suggests that it could grow by 489.17%. Given that ESSA Pharma has higher upside potential than Milestone Pharmaceuticals, analysts believe ESSA Pharma is more attractive than Milestone Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings MISTMilestone Pharmaceuticals0 0 0 EPIXESSA Pharma0 4 0 -
Is MIST or EPIX More Risky?
Milestone Pharmaceuticals has a beta of 1.826, which suggesting that the stock is 82.646% more volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.388%.
-
Which is a Better Dividend Stock MIST or EPIX?
Milestone Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Pharmaceuticals pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIST or EPIX?
Milestone Pharmaceuticals quarterly revenues are --, which are smaller than ESSA Pharma quarterly revenues of --. Milestone Pharmaceuticals's net income of -$9.4M is lower than ESSA Pharma's net income of -$6.4M. Notably, Milestone Pharmaceuticals's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Pharmaceuticals is -- versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MISTMilestone Pharmaceuticals-- -- -- -$9.4M EPIXESSA Pharma-- -- -- -$6.4M
-
Which has Higher Returns MIST or LEXX?
Lexaria Bioscience has a net margin of -- compared to Milestone Pharmaceuticals's net margin of -2121.06%. Milestone Pharmaceuticals's return on equity of -- beat Lexaria Bioscience's return on equity of -93.31%.
Company Gross Margin Earnings Per Share Invested Capital MISTMilestone Pharmaceuticals-- -$0.14 -- LEXXLexaria Bioscience-- -$0.13 $9.7M -
What do Analysts Say About MIST or LEXX?
Milestone Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 454.05%. On the other hand Lexaria Bioscience has an analysts' consensus of -- which suggests that it could grow by 352.49%. Given that Milestone Pharmaceuticals has higher upside potential than Lexaria Bioscience, analysts believe Milestone Pharmaceuticals is more attractive than Lexaria Bioscience.
Company Buy Ratings Hold Ratings Sell Ratings MISTMilestone Pharmaceuticals0 0 0 LEXXLexaria Bioscience0 0 0 -
Is MIST or LEXX More Risky?
Milestone Pharmaceuticals has a beta of 1.826, which suggesting that the stock is 82.646% more volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.234%.
-
Which is a Better Dividend Stock MIST or LEXX?
Milestone Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Pharmaceuticals pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIST or LEXX?
Milestone Pharmaceuticals quarterly revenues are --, which are smaller than Lexaria Bioscience quarterly revenues of $84K. Milestone Pharmaceuticals's net income of -$9.4M is lower than Lexaria Bioscience's net income of -$1.8M. Notably, Milestone Pharmaceuticals's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Pharmaceuticals is -- versus 58.77x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MISTMilestone Pharmaceuticals-- -- -- -$9.4M LEXXLexaria Bioscience58.77x -- $84K -$1.8M
-
Which has Higher Returns MIST or XENE?
Xenon Pharmaceuticals has a net margin of -- compared to Milestone Pharmaceuticals's net margin of --. Milestone Pharmaceuticals's return on equity of -- beat Xenon Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MISTMilestone Pharmaceuticals-- -$0.14 -- XENEXenon Pharmaceuticals-- -$0.81 -- -
What do Analysts Say About MIST or XENE?
Milestone Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 454.05%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.67 which suggests that it could grow by 50.1%. Given that Milestone Pharmaceuticals has higher upside potential than Xenon Pharmaceuticals, analysts believe Milestone Pharmaceuticals is more attractive than Xenon Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings MISTMilestone Pharmaceuticals0 0 0 XENEXenon Pharmaceuticals11 0 0 -
Is MIST or XENE More Risky?
Milestone Pharmaceuticals has a beta of 1.826, which suggesting that the stock is 82.646% more volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.926%.
-
Which is a Better Dividend Stock MIST or XENE?
Milestone Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Pharmaceuticals pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIST or XENE?
Milestone Pharmaceuticals quarterly revenues are --, which are smaller than Xenon Pharmaceuticals quarterly revenues of --. Milestone Pharmaceuticals's net income of -$9.4M is higher than Xenon Pharmaceuticals's net income of -$62.8M. Notably, Milestone Pharmaceuticals's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Pharmaceuticals is -- versus 221.08x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MISTMilestone Pharmaceuticals-- -- -- -$9.4M XENEXenon Pharmaceuticals221.08x -- -- -$62.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
